retatrutide glucagon receptor More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and receptors In the Phase Retatrutide in Obesity and Diabetes
Pay in 4 interest-free payments of $6.73 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
























